---
name: deal-economics
description: >
  Apply biotech deal structure frameworks including licensing economics, M&A
  valuation premiums, royalty rate benchmarks, milestone design principles, and
  option-based deal architectures for biotech venture investment analysis and
  partnership evaluation.
metadata:
  author: nirav
  version: "1.0"
compatibility: Designed for Claude Code
allowed-tools: Read, WebSearch, WebFetch
---

# Deal Economics — The Transaction Intelligence Framework

Every biotech asset has two valuations: the intrinsic value (rNPV of the program) and the transaction value (what someone will pay for it in a deal). This skill bridges that gap by providing the frameworks, benchmarks, and structural knowledge needed to evaluate licensing deals, M&A transactions, and partnership economics. In a sector where 70%+ of clinical-stage programs are eventually partnered or acquired, deal economics is not optional knowledge — it is the exit strategy.

The biotech deal market has undergone a structural shift in 2024-2025: upfronts now represent only about 7% of total deal value, milestone-heavy structures dominate, and China out-licensing has emerged as a major value creation pathway.

## Core Frameworks

> **Comparables data:** For sourced, vintage-tagged royalty/upfront/milestone splits, modality deal cuts, M&A benchmarks, and named 2023–2024 transactions, use `references/deal-comps-benchmarks.md`. These numbers stale within 6–12 months — re-pull from primary sources before a live memo.

### Framework 1 — Licensing Deal Structure

A biotech licensing deal has four economic components, each serving a different function:

| Component | Function | Typical Range | Negotiation Dynamics |
|---|---|---|---|
| **Upfront payment** | Risk premium to licensor; sunk cost for licensee | 5-15% of total deal value | Biotech needs cash; pharma wants option-like exposure |
| **Development milestones** | Aligns payment with de-risking events | 20-35% of total deal value | Triggered by IND, Phase start, data readout, filing |
| **Commercial milestones** | Aligns payment with revenue achievement | 15-25% of total deal value | Tiered sales thresholds ($500M, $1B, $2B, $5B) |
| **Royalties** | Ongoing share of product economics | See royalty benchmarks below | Rate depends on stage, contribution, and territory |

**The 25-35% Rule.** Across hundreds of licensing deals, licensors typically receive 25-35% of the licensee's risk-adjusted NPV as total deal value. This is the fundamental anchor for deal valuation:

```
Total Deal Value = Licensee's rNPV of the Asset x 0.25-0.35
```

This ratio holds because:
- The licensor takes early-stage risk and generates the IP
- The licensee provides capital, development infrastructure, and commercial capability
- The 25-35% range reflects the relative contribution and remaining risk

**Deal value by phase (2024-2025 benchmarks):**

| Stage at Deal | Median Total Deal Value | Median Upfront | Upfront as % of Total |
|---|---|---|---|
| Preclinical | $200-600M | $10-40M | 5-8% |
| Phase 1 | $400M-$1.2B | $25-80M | 5-10% |
| Phase 2 | $800M-$3B | $100-500M | 10-20% |
| Phase 3 | $1.5-5B+ | $300M-$1.5B | 15-30% |
| Approved / Commercial | rNPV-based M&A | Full acquisition | 100% (acquisition premium) |

**Key trend (2022-2024):** Phase II upfronts jumped approximately 460% from 2022 to 2024, reflecting pharma's urgency to refill pipelines and increased competition for de-risked assets.

### Framework 2 — Royalty Rate Benchmarks

Royalties are the most NPV-sensitive deal term because they compound over the entire commercial life of the product. Rates are determined by stage, modality, territory, and licensor contribution:

| Factor | Lower Royalty (1-5%) | Mid Royalty (8-15%) | Higher Royalty (15-25%) |
|---|---|---|---|
| Stage at deal | Preclinical / early discovery | Phase 1-2 | Phase 3 / approved |
| Licensor contribution | Target only or platform access | Lead molecule + IND | Clinical package + regulatory dossier |
| Territory | Single territory (ex-US) | Major market (US or EU) | Global rights |
| Competitive dynamics | Single bidder | 2-3 interested parties | Competitive auction |

**Royalty benchmarks by modality and stage:**

| Scenario | Typical Royalty Range |
|---|---|
| Early-stage small molecule (preclinical) | 1-5% of net sales |
| Phase 1 monoclonal antibody | 5-10% of net sales |
| Phase 2 biologic with positive data | 10-18% of net sales |
| Phase 3 biologic / near-approval | High teens to low 20s% |
| Approved product (commercial stage) | 15-25% (or M&A preferred) |
| Platform technology (multi-target) | 2-5% per product + upfront for platform access |
| Bispecific / ADC (complex modality) | Mid-teens% (premium for manufacturing know-how) |

**Royalty stacking.** When a product requires licenses from multiple IP holders, total royalty burden can reach 15-30%, squeezing licensee economics. Deals typically include anti-stacking provisions capping total third-party royalties at 50% reduction of the base rate.

### Framework 3 — M&A Valuation Premiums

When pharma acquires a biotech outright rather than licensing, the acquisition premium over the pre-announcement stock price reflects the value transfer:

| Phase of Lead Asset | Median Acquisition Premium | Range |
|---|---|---|
| Preclinical | 80-150% | Wide range; platform vs. single-asset |
| Phase 1 | 60-100% | Lower premiums, higher risk |
| Phase 2 (pre-data) | 50-80% | Waiting for proof-of-concept |
| Phase 2 (positive data) | 80-150% | Data de-risks; bidding wars possible |
| Phase 3 | 40-70% | More predictable value, lower upside |
| Approved / commercial | 30-50% | Revenue visible, less speculation |

**Hostile vs. friendly.** Hostile bids typically require 20-30% higher premiums than negotiated deals. In biotech, most deals are negotiated because boards have fiduciary duty to maximize shareholder value and will run competitive processes.

**Strategic premium vs. financial premium.** Strategic acquirers (pharma with commercial synergies) pay 20-40% more than financial acquirers (PE, royalty funds) because they capture commercial synergies.

### Framework 4 — Mega-Deal Benchmarks (2024-2025)

The current deal cycle is the most active since 2019. Key reference transactions:

| Deal | Total Value | Structure | Significance |
|---|---|---|---|
| Daiichi Sankyo-Merck (ADC) | $22B | $4B upfront + $18B milestones | Largest pharma licensing deal; validates ADC platform |
| AstraZeneca-CSPC (oncology) | $18.5B | Tiered milestones | Largest China-originated out-license |
| BioNTech-BMS (oncology) | $11.1B | Upfront + milestones | mRNA platform validation beyond COVID |
| Roche-Zealand (obesity/cardiometabolic) | $5.3B | Significant upfront | Pharma's obesity gold rush continues |

**China out-licensing wave.** In 2025, Chinese biotech companies completed approximately 157 out-licensing deals worth a combined $135.7B in total deal value — nearly triple the 2024 total. This reflects maturing Chinese drug development capability and Western pharma's appetite for novel assets and lower development costs.

### Framework 5 — Option-Based Deal Architectures

Modern biotech deals increasingly use option structures that give the licensee the right (but not obligation) to exercise rights at a future de-risking event:

| Structure | How It Works | When Used |
|---|---|---|
| **Opt-in after Phase 2** | Licensee pays small upfront + funds Phase 1-2; option to license global rights after Phase 2 data | Early-stage platform deals; licensee manages risk |
| **Co-development with opt-out** | Partners split costs 50/50; either party can opt out at pre-specified decision point | Balanced-power partnerships; shared risk |
| **Royalty buy-down** | Licensor can invest in Phase 3 costs to increase royalty rate | Allows biotech to capture more economics if well-capitalized |
| **Territory split** | Licensor retains US rights, licenses ex-US | Biotech builds US commercial capability while monetizing ROW |

### Framework 6 — Milestone Design Principles

Well-designed milestones align value transfer with risk reduction:

| Milestone Type | Best Practice | Common Pitfall |
|---|---|---|
| Development milestones | Tie to objective events (IND acceptance, first patient dosed, primary endpoint met) | Subjective milestones that create disputes |
| Regulatory milestones | Tie to filing acceptance and approval, not submission | Counting submission as milestone before FDA accepts |
| Commercial milestones | Use net sales thresholds, not gross | Gross sales milestones overstate achievement |
| Escalating milestones | Back-load to match de-risking curve | Front-loading gives too much too early |
| Anti-shelving provisions | Include diligence obligations and reversion rights | Licensor loses control if licensee deprioritizes |

## How to Apply

### Input

| Parameter | Required? | Example |
|---|---|---|
| Asset stage | Yes | Phase 2 with positive data |
| Modality | Yes | ADC |
| Therapeutic area | Yes | Oncology (breast cancer) |
| Deal type under evaluation | Yes | Out-licensing, M&A, co-development |
| Peak sales estimate | Recommended | $2.5B (from peak-sales-forecaster) |
| rNPV of program | Recommended | $1.2B (from rNPV model) |

### Output

```
DEAL ECONOMICS ANALYSIS — [Asset Name]
Deal Type: [licensing / M&A / co-development]
Stage: [phase]
Date: [assessment date]

DEAL VALUATION RANGE:
  rNPV of program:                    $[X]M
  25-35% Rule range:                  $[X]-[Y]M (total deal value to licensor)
  Phase-appropriate upfront:          $[X]-[Y]M ([X]% of total)

RECOMMENDED DEAL STRUCTURE:
  Upfront:                            $[X]M
  Development milestones:             $[X]M ([list key triggers])
  Regulatory milestones:              $[X]M
  Commercial milestones:              $[X]M ([sales thresholds])
  Total milestones:                   $[X]M
  Royalty rate:                       [X]-[Y]% of net sales
  TOTAL DEAL VALUE:                   $[X]M

M&A ALTERNATIVE:
  Current market cap:                 $[X]M
  Implied acquisition premium:        [X]-[Y]%
  Implied acquisition price:          $[X]-[Y]M
  Premium vs. licensing economics:    [comparison]

DEAL COMPARABLES:
  [Comparable deal 1: terms summary]
  [Comparable deal 2: terms summary]
  [Comparable deal 3: terms summary]

KEY NEGOTIATION LEVERS:
  1. [Most impactful term to negotiate]
  2. [Second most impactful]
  3. [Territory structure consideration]
```

### Error Handling

| Scenario | Response |
|---|---|
| No comparable deals in modality/TA | Use closest available analog; adjust for modality complexity premium or TA risk; clearly state the limitation |
| Pre-revenue company (no rNPV anchor) | Use stage-based deal value benchmarks; triangulate with comparable financing valuations; present wider range |
| Multi-asset deal (platform + programs) | Separate platform access value from individual program value; platform deals typically command 2-3x single-asset economics |
| Cross-border deal (different regulatory territories) | Apply territory-specific pricing and market size adjustments; note that China-to-US out-licenses may include data package transfer premiums |
| Auction dynamics (multiple bidders) | Premiums increase 20-40% in competitive auctions; model both negotiated and auction scenarios |

## Cross-Domain Connections

- **Biotech-venture/peak-sales-forecaster**: Peak sales drives total deal value through the 25-35% rule and royalty NPV
- **Biotech-venture/pos-calculator**: PoS determines risk-adjustment in rNPV that anchors deal valuation
- **Biotech-venture/cost-estimator**: Remaining development costs inform upfront sizing and milestone structure
- **Biotech-venture/competitive-intelligence**: Competitive dynamics affect deal urgency and bidding competition
- **Biotech-venture/deal-synthesis**: Orchestrates deal economics with other valuation inputs into investment recommendations